Anthracycline News and Research

RSS

Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.

Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy

Ultrasound provides a safe and accurate method of detecting breast cancers in pregnant women, as well as assessing response to chemotherapy, according to a study appearing in the April issue of Radiology.

13 Apr 2006

Great news for breast cancer patients

In encouraging new study results researchers say that modern treatments have significantly boosted the 15-year survival rate for breast cancer, and even better news is that they have also found that drug and hormonal therapies effectively cure many women, rather than simply delaying the recurrence of disease.

12 May 2005

Herceptin - more powerful treatment for patients with HER-2-positive breast cancer

A new use of the drug Herceptin appears to offer a much more powerful treatment advantage than expected for patients with HER-2-positive breast cancer, say researchers at The University of Texas M. D. Anderson Cancer Center.

29 Mar 2005

Launch date announced for Abraxane to treat metastatic breast cancer

American Pharmaceutical Partners announced today that February 8, 2005 is the launch date of Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). Abraxane will be marketed by the national sales force of Abraxis Oncology, APP's proprietary sales and marketing division.

25 Jan 2005

FDA approves Abraxane for metastatic breast cancer

American Pharmaceutical Partners, Inc. and American Bioscience, Inc. (ABI) announced that the U.S. Food and Drug Administration (FDA) has approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in metastatic breast cancer.

9 Jan 2005

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire all outstanding equity of Aesgen for $32 million in cash.

1 Sep 2004

First patient dosed with Tesmilifene in pivotal breast cancer study

YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.

31 Mar 2004